



Rationale Objective

Study Schema

Treatment Plan

Eligibility Criteria

Follow Up

Please use the headings above to navigate through the different sections of the poster

Alliance A221505: RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Matthew M. Poppe, MD

Huntsman Cancer Hospital, University of Utah

Objective



TAP TO RETURN TO

KIOSK MENU


A program of the National Cancer Institute of the National Institutes of Health

Primary

- Non-inferior reconstruction complication rate at 24 months post radiation with hypofractionation.
- Complications will include any re-operation or hospitalization considered as non-routine, as well any baker 3 or 4 contracture

Secondary

- · Acute and late radiation complications, based on CTCAE 4.0 toxicity.
- · Local and local regional recurrence rate.
- Photographic cosmesis 24 months after radiation.
- Lymphedema at 24 months after radiation.
- Patient satisfaction and well-being at 24 months after radiation (Breast Q)
- Compare reconstruction complication rates based on reconstruction method and timing of reconstruction.
- · Cost and healthcare utilization based on hypofractionation and reconstruction technique





Alliance A221505: RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Matthew M. Poppe, MD

Huntsman Cancer Hospital, University of Utah

Treatment Plan



TAP TO

RETURN TO

A program of the National Cancer Institute of the National Institutes of Health

Rationale Objective

Study Treat

Eligib Follov

Please heading navigate differen the pos

ctive	Surgery	Reconstruction	Radiation Therapy	Chemotherapy
y Schema tment Plan oility Criteria ow Up	 Total, simple, skin sparing, nipple sparing or modified radical mastectomy. Margins should be negative, defined as no tumor on ink. Focally positive deep margin will be acceptable if the deep margin is the pectoralis fascia and the pectoralis fascia was noted as removed in the operative description or pathology report. Lymph nodes must be evaluated by sentinel node biopsy or axillary dissection. If contralateral breast surgery, no invasive disease in contra-lateral breast (DCIS okay) 	 Reconstruction of the breast may occur before of after radiation. Tissue expander may be placed before or after radiation and maybe inflated or deflated for radiation Plastic surgeon may use any combination of allograft, implant or tissue flap for reconstruction. Reconstruction intent must be stated at the time of registration (timing and implant vs. autologous) Intent to complete reconstruction within 8 months of radiation (approximately 1 year from mastectomy) 	 Similar volume based planning to A11202 and NSABP B51. RT must start within 84 days of mastectomy or adjuvant chemo (whichever is later) 2.66Gy x 16 daily to reconstructed CW and regional nodes (IM coverage required). No boost allowed. RT QA through IROC Rhode Island Data submission within 3 days of starting RT IMRT QA grand-fathered if completed for A11202/B51 Proton RT not allowed at this time 	 Per standard of care Neoadjuvant or adjuvant allowed May be delivered before or after PMRT No concurrent chemotherapy with RT other than anti-Her2 or other biological therapy Minimum 21 days between chemotherapy and RT Adjuvant hormonal therapy per treating physician If Neoadjuvant chemotherapy, surgery must occur within 56 days of finishing chemotherapy



Rationale

Objective

Study Schema

Treatment Plan

Eligibility Criteria

Follow Up

Please use the headings above to navigate through the different sections of the poster

Alliance A221505: RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Matthew M. Poppe, MD

Huntsman Cancer Hospital, University of Utah

Eligibility Criteria



TAP TO RETURN TO

KIOSK MENU

A program of the National Cancer Institute of the National Institutes of Health

- Women ≥ 18 years of age.
- ECOG performance status of 0 or 1.
- Invasive breast cancer of any histology. No prior ipsilateral breast cancer (invasive or DCIS). Contralateral DCIS okay, no invasive.
- AJCC Stage IIa –IIIa . T4, N3 and involved internal mammary disease (N1b, N1c, and N2b) will not be allowed.
- Clinical N1 or N2 disease prior to induction chemotherapy are allowed if pathologically N0-N2 at the time of mastectomy.
- Treating physician must plan to deliver regional nodal radiation.
- Negative inked histologic margins of mastectomy.
- · Chemo allowed neoadjuvant or adjuvant (before or after RT).
- Planned chest wall reconstruction is required with intent declared for autologous vs. implant and immediate vs. delayed reconstruction before randomization.
- Reconstruction can take place before or after post mastectomy radiation.

